TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Price, Quote, News and Summary
NASDAQ:TNXP - Nasdaq - US8902608475 - Common Stock
TNXP Quote and Key Statistics
TONIX PHARMACEUTICALS HOLDIN
NASDAQ:TNXP (1/21/2025, 8:00:02 PM)
After market: 0.2348 0 (-1.72%)0.2389
+0 (+1.44%)
TNXP Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -142.38% | ||
| ROE | -182.25% | ||
| Debt/Equity | 0.07 |
TNXP Performance and Technical Analysis
TNXP Ownership and Analysts
TNXP Latest News and Analysis
Wednesday's after hours session: top gainers and losers
After hours stock analysis on 2025-01-15: top gainers and losers in today's session.
Tonix Pharmaceuticals to Present at Two Upcoming January Investor Conferences
CHATHAM, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company...
Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia
Tonix received FDA’s Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a...
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in the Day 74...
About TNXP
Company Profile
Tonix Pharmaceuticals Holding Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Chatham, New Jersey and currently employs 103 full-time employees. The company went IPO on 2010-03-29. Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include Tonmya (TNX-102 SL), TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801 and TNX-1800. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Company Info
TONIX PHARMACEUTICALS HOLDIN
26 Main Street, Suite 101
Chatham NEW JERSEY 07928 US
CEO: Seth Lederman
Employees: 103
Company Website: https://www.tonixpharma.com/
Investor Relations: https://ir.tonixpharma.com/
Phone: 12129809155
TNXP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 16.06 | 305.03B | ||
| AMGN | AMGEN INC | 14.3 | 147.72B | ||
| GILD | GILEAD SCIENCES INC | 20.98 | 115.85B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 839 | 110.19B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.14 | 75.58B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.18B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.26B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.28B | ||
| NTRA | NATERA INC | N/A | 22.11B | ||
| BIIB | BIOGEN INC | 8.63 | 20.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.16 | 16.43B |